Stock FBRX FORTE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Forte Biosciences, Inc.

Equities

FBRX

US34962G1094

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.725 USD +1.21% Intraday chart for Forte Biosciences, Inc. +0.69% -11.77%
Mar. 18 Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 05 Camac Partners Provides Information to Shareholders CI

Evolution of the average Target Price on Forte Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

500f2ce71e8.Kq_h4mDa2w2_uQFcuQ0F2ATYhsJrOEpRrdpAYKI2zg0.TPuFjFmigkb07SwUyGVSoVyosKcYaS0pyKlzEZpDg10am7akEInjP-7DTA~878ff20faa758b3c14012e43dee47576

Analyst Recommendations on Forte Biosciences, Inc.

FORTE BIOSCIENCES : Chardan Capital Upgrades Forte Biosciences to Neutral From Sell Following Recent Selloff, Adjusts Price Target to $3.50 From $4 MT
FORTE BIOSCIENCES : Ladenburg Thalmann Downgrades Forte Biosciences to Neutral From Buy MT
FORTE BIOSCIENCES : Brookline Capital Downgrades Forte Biosciences to Hold from Buy MT
FORTE BIOSCIENCES : Chardan Downgrades Forte Biosciences to Sell From Buy, Adjusts Price Target to $4 From $105; Shares Slide 80% Premarket MT
FORTE BIOSCIENCES : Ladenburg Thalmann Downgrades Forte Biosciences to Neutral from Buy MT
FORTE BIOSCIENCES : B. Riley Downgrades Forte Biosciences to Neutral from Buy After Lead Program FB-401 Failed to Strike Primary Endpoint, Lowers PT to $3 from $73 MT
FORTE BIOSCIENCES : Truist Securities Downgrades Forte Biosciences to Hold from Buy MT
FORTE BIOSCIENCES : B. Riley Starts Forte Biosciences at Buy with $73 PT, Says FB-401 Could Fill Gap for Steroid-Free Treatment for Atopic Dermatitis MT
FORTE BIOSCIENCES : Citigroup Starts Forte Biosciences at Buy With $75 Price Target MT
FORTE BIOSCIENCES : Chardan Capital Adjusts Price Target on Forte Biosciences to $105 From $115, Maintains Buy Rating MT
FORTE BIOSCIENCES : Chardan Adjusts Forte Biosciences' Price Target to $115 From $110, Keeps at Buy MT
Forte Biosciences : Shares Higher After Truist Initiates Coverage DJ
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7163 USD
Average target price
2.875 USD
Spread / Average Target
+301.37%
High Price Target
3 USD
Spread / Highest target
+318.82%
Low Price Target
2.75 USD
Spread / Lowest Target
+283.92%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Forte Biosciences, Inc.

Chardan
Brookline Capital Management
Ladenburg Thalmann
Truist Securities
B. Riley
Citigroup

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. FBRX Stock
  4. Consensus Forte Biosciences, Inc.